Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 9, 2007, Pages 3049-3055

  Vinks, Alexander A ^a,f   Van Rossem, Ronald N ^b   Mathôt, Ron A A ^c   Heijerman, Harry G M ^d   Mouton, Johan W ^e  

^a UNIVERSITY OF CINCINNATI   (United States)

^b REINIER DE GRAAF HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HAGA HOSPITAL   (Netherlands)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; MONOBACTAM DERIVATIVE;

ADULT; ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG URINE LEVEL; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SINGLE DRUG DOSE;

ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; AZTREONAM; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; MALE; MODELS, STATISTICAL; MONTE CARLO METHOD;

EID: 35948951943     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01522-06     Document Type: Article

References (43)

1. Ambrose, P. G. 2006. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future: insights from the society of infectious diseases pharmacists. Pharmacotherapy 26:129-134.
2. Ambrose, P. G., and D. M. Grasela. 2000. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38:151-157.
3. Anderson, B. J., K. Allegaert, and N. H. Holford. 2006. Population clinical pharmacology of children: modeling covariate effects. Eur. J. Pediatr. 165:819-829.
4. Bayer, A. S., D. Crowell, C. C. Nast, D. C. Norman, and R. L. Borrelli. 1990. Intravegetation antimicrobial distribution in aortic endocarditis analyzed by computer-generated model. Implications for treatment. Chest 97:611-617.
5. Bonate, P. L. 2001. A brief introduction to Monte Carlo simulation. Clin. Pharmacokinet. 40:15-22.
6. Bosso, J., and P. Black. 1988. Controlled trial of aztreonam versus tobra-mycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr. Infect. Dis. J. 7:171-176.
7. Bosso, J., P. Black, and J. Matsen. 1987. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. Pediatr. Infect. Dis. J. 6:393-397.
8. Bradley, J. S., M. N. Dudley, and G. L. Drusano. 2003: Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr. Infect. Dis. J. 22:982-995.
9. Bustad, A., D. Terziivanov, R. Leary, R. Port, A. Schumitzky, and R. Jelliffe. 2006. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin. Pharmacokinet. 45:365-383.
10. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
11. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
12. de Groot, R., and A. L. Smith. 1987. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin. Pharmacokinet. 13:228-253.
13. Drusano, G. L., D. Z. D'Argenio, S. L. Preston, C. Barone, W. Symonds, S. LaFon, M. Rogers, W. Prince, A. Bye, and J. A. Bilello. 2000. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir. Antimicrob. Agents Chemother. 44:1655-1659.
14. Drusano, G. L., S. L. Preston, C. Hardalo, R. Hare, C. Banfleld, D. Andes, O. Vesga, and W. A. Craig. 2001. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45:13-22.
15. DuBois, D., and E. DuBois. 1916. A formula to estimate the appropriate surface area if height and weight are known. Arch. Intern. Med. 17:863-871.
16. EUCAST. 2006. Aztreonam - EUCAST clinical MIC breakpoints, 2006-06-20 (v.1.2). European Committee on Antimicrobial Susceptibility Testing, European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland. [Online.] http://www.srga.org/eucastwt/MICTAB/MICaztreonam.html.
17. Hallynck, T. H., H. H. Soep, J. A. Thomis, J. Boelaert, R. Daneels, and L. Dettli. 1981. Should clearance be normalized to body surface or to lean body mass? Br. J. Clin. Pharmacol. 11:523-526.
18. Jehl, F., P. Birckel, and H. Monteil. 1987. Hospital routine analysis of penicillins, third-generation cephalosporins, and aztreonam by conventional and high-speed high-performance liquid chromatography. J. Chromatogr. 413:109-119.
19. Jelliffe, R. 2000. Goal-oriented, model-based drug regimens: setting individualized goals for each patient. Ther. Drug Monit. 22:325-329.
20. Jelliffe, R. W., and S. Jelliffe. 1972. A computer program for the estimation of creatinine clearance from unstable serum creatinine concentration. Math. Biosci. 14:17-24.
21. Jelliffe, R. W., A. Schumitzky, and M. Van Guilder. 1995. User manual for version 10.7 of the USC*PACK collection of PC programs. Laboratory of Applied Pharmacokinetics, University of Southern California, School of Medicine, Los Angeles, CA.
22. Leary, R., R. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. Proceedings of the 14th Institute of Electrical and Electronics Engineers Symposium on Computer-Based Medical Systems, p. 389-394. IEEE, Bethcsda, MD.
23. Mattie, H. 1988. Clinical pharmacokinetics of aztreonam. Clin. Pharmacokinet. 14:148-155.
24. Mattie, H. 1994. Clinical pharmacokinetics of aztreonam: an update. Clin. Pharmacokinet. 26:99-106.
25. Montgomery, M. J., P. M. Beringer, A. Aminimanizani, S. G. Louie, B. J. Shapiro, R. Jelliffe, and M. A. Gill. 2001. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 45:3468-3473.
26. Mouton, J. W. 2003. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect. Dis. Clin. N. Am. 17:579-598.
27. Mouton, J. W., N. Jacobs, H. Tiddens, and A. M. Horrevorts. 2005. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn. Microbiol. Infect. Dis. 52:123-127.
28. Mouton, J. W., N. Punt, and A. A. Vinks. 2005. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin. Ther. 27:762-772.
29. Mouton, J. W., A. Schmitt-Hoffmann, S. Shapiro, N. Nashed, and N. C. Punt. 2004. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 48:1713-1718.
30. Reed, M. D., S. C. Aronoff, and R. C. Stern. 1985. Single-dose pharmacokinetics of aztreonam in cystic fibrosis. Clin. Pharmacol. Ther. 37:223.
31. Reed, M. D., S. C. Aronoff, R. C. Stern, T. S. Yamashita, C. M. Myers, L. T. Friedhoff, and J. L. Blumer. 1986. Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis. Pediatr. Pulmonol. 2:282-286.
32. Rey, E., J. M. Treluyer, and G. Pons. 1998. Drug disposition in cystic fibrosis. Clin. Pharmacokinet. 35:313-329.
33. Salh, B., D. Bilton, M. Dodd, J. Abbot, and K. Webb. 1992. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis. Scand. J. Infect. Dis. 24:215-218.
34. Scully, B. E., C. N. Ores, A. S. Prince, and H. C. Neu. 1985. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Rev. Infect. Dis. 7(Suppl. 4):S669-S674.
35. Smith, P. F., C. H. Ballow, B. M. Booker, A. Forrest, and J. J. Schentag. 2001. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin. Ther. 23:1231-1244.
36. Sorgel, F., U. Stephan, H. G. Wiesemann, B. Gottschalk, C. Stehr, M. Rey, H. B. Bowing, H. C. Dominick, and M. Geldmacher von Mallinckrodt. 1987. High-dose treatment with antibiotics in cystic fibrosis: a reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF patients. Infection 15:385-396.
37. Spino, M. 1991. Pharmacokinetics of drugs in cystic fibrosis. Clin. Rev. Allergy 9:169-210.
38. Swabb, E. A. 1985. Review of the clinical pharmacology of the monobactam antibiotic aztreonam. Am. J. Med. 78:11-18.
39. Swabb, E. A., M. A. Leitz, F. G. Pilkiewicz, and A. A. Sugerman. 1981. Pharmacokinetics of the monobactam SQ 26,776 after single intravenous doses in healthy subjects. J. Antimicrob. Chemother. 8(Suppl. E):131-140.
40. Touw, D. J., A. A. Vinks, F. Jacobs, H. G. Heijerman, and W. Bakker. 1996. Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis. Ther. Drug Monit. 18:562-569.
41. Vinks, A. A., R. W. Brimicombe, H. G. Heijerman, and W. Bakker. 1997. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J. Antimicrob. Chemother. 40:125-133.
42. Vinks, A. A., D. J. Touw, R. C. van Rossen, H. G. Heijerman, and W. Bakker. 1996. Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT). Pharm. World Sci. 18:74-77.
43. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet Biopharm. 6:165-175.